Holen Sie sich die Stockscreener-App
1.82
0.55%
-0.01
Handel nachbörslich:
1.70
-0.12
-6.59%
Schlusskurs vom Vortag:
$1.83
Offen:
$1.83
24-Stunden-Volumen:
70,929
Relative Volume:
0.63
Marktkapitalisierung:
$151.93M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-2.4819
EPS:
-0.7333
Netto-Cashflow:
$21.84M
1W Leistung:
+8.33%
1M Leistung:
-9.90%
6M Leistung:
-20.52%
1J Leistung:
+40.00%
1-Tages-Spanne:
$1.81
$1.94
1-Wochen-Bereich:
$1.65
$2.05
52-Wochen-Spanne:
$1.11
$3.29
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com UK
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - StockTitan
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - SETE News
What technical indicators reveal about PRQR stock - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK
ProQR Therapeutics NV (FRA:0PQ) Financial Strength : 3 (As of Jun. 2024) - GuruFocus.com
Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN) - Defense World
ProQR Therapeutics NV (FRA:0PQ) Enterprise Value : €86.81 Mil (As of Aug. 17, 2024) - GuruFocus.com
Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR: Q2 Earnings Snapshot - San Antonio Express-News
ProQR: Q2 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics N.V. Financial Performance Review - TipRanks
ProQR Announces Second Quarter 2024 Operating and Financial Results - GlobeNewswire
ProQR Announces Second Quarter 2024 Operating and Financial Results - Yahoo Finance
Virtu Financial LLC Has $59,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Acadian Asset Management LLC Takes $56,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $2.00 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Two Hundred Day Moving Average of $2.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $2.01 - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected - Simply Wall St
StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to Hold - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Drop in Short Interest - MarketBeat
StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to “Hold” - Defense World
Individual investors account for 45% of ProQR Therapeutics N.V.'s (NASDAQ:PRQR) ownership, while institutions ... - Yahoo New Zealand News
ProQR (PRQR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK
RFG Advisory LLC Makes New $73,000 Investment in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly - Yahoo Canada Shine On
ProQR Announces Upcoming Investor Conferences in November and December - Quantisnow
Lilly and ProQR to Expand RNA Editing Collaboration - Quantisnow
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock? - Zacks Investment Research
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the ... - Yahoo Finance UK
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the company - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) Lowered to Sell at StockNews.com - Defense World
StockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to Sell - MarketBeat
ProQR (PRQR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo New Zealand News
A stock that deserves closer examination: ProQR Therapeutics N.V (PRQR) – US Post News - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Markets Insider
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - EIN News
PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - ForexTV.com
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):